1253789-90-0

Basic information

• Product Name: isopropyl 3-cyclopentyl-1-methyl-1H-indole-6-carboxylate
• Synonyms: isopropyl 3-cyclopentyl-1-methyl-1H-indole-6-carboxylate
• CAS NO: 1253789-90-0
• Molecular Formula: C18H23NO2
• Molecular Weight: 285.38072
• Mol File: 1253789-90-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: isopropyl 3-cyclopentyl-1-methyl-1H-indole-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: isopropyl 3-cyclopentyl-1-methyl-1H-indole-6-carboxylate(1253789-90-0)
• EPA Substance Registry System: isopropyl 3-cyclopentyl-1-methyl-1H-indole-6-carboxylate(1253789-90-0)

Safety Data

• Hazardous Substances Data: 1253789-90-0(Hazardous Substances Data)

Usage

General Description

Isopropyl 3-cyclopentyl-1-methyl-1H-indole-6-carboxylate, also known as Etizolam, is a psychoactive drug that belongs to the thienodiazepine class and is commonly used as a treatment for anxiety and insomnia. It acts as a central nervous system depressant and works by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain. This results in a calming and sedative effect, alleviating symptoms of anxiety and promoting relaxation and sleep. Etizolam is available in various forms such as tablets, powders, and liquids, and is often used off-label for its euphoric and sedative effects. However, it is important to note that Etizolam has a high potential for abuse and dependence and should be used with caution under the supervision of a medical professional.

Upstream product

• 905856-76-0 C₂₂H₃₀BNO₄ 
• 494799-35-8 2-bromo-3-cyclopentyl-1-methylindole-6-carboxylic acid methyl ester 
• 494799-36-9 3-cyclopentylindole-6-carboxylic acid 
• 120-92-3 cyclopentanone 
• 1670-82-2 Indole-6-carboxylic acid 
• 494799-38-1 3-cyclopentyl-1-methylindole-6-carboxylic acid methyl ester 
• 2388-10-5 lithium isopropoxide 
• 67-63-0 isopropyl alcohol 

Downstream Products

• 1370023-80-5 (E)-3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid sodium salt 
• 1461641-21-3 (E)-3-[2-(1-{[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]amino}cyclobutyl)-3-methyl-3H-benzimidazol-5-yl]acrylic acid 

Relevant articles and documents

A highly concise and convergent synthesis of HCV polymerase inhibitor Deleobuvir (BI 207127): Application of a one-pot borylation-suzuki coupling reaction

A highly concise and convergent synthesis of HCV polymerase inhibitor Deleobuvir (BI 207127, 1) was achieved, featuring efficient Pd-catalyzed one-pot borylation-Suzuki coupling where TFP was identified as the unique ligand effective for these transformations.

ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS

The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient that has genetic variations located near the IL28B gene, including SNP rs 12979860 with a CC or non-CC genotype and SNP rs 8099917 with a TT or non-TT genotype.

ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS

The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally